Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sen. Kohl Joins Ranks Of DTC Legislation Sponsors

This article was originally published in The Pink Sheet Daily

Executive Summary

The Wisconsin Democrat's forthcoming bill would follow the "FDA Safety Act" and the "Pharmaceutical Advertising & Prudent Purchasing Act," both currently pending.

You may also be interested in...

FDA To Convene Two-Day Meeting On DTC Advertising

Agency requests public comment for Nov. 1-Nov. 2 meeting on risk/benefit information dissemination, presentation of brief summary for drugs, devices, vaccines and blood products.

Sen. Frist's Diagnosis On DTC: GAO Report, Two-Year Moratorium For New Drugs

Majority Leader Frist requests Government Accountability Office examine FDA's oversight of direct-to-consumer ads and their impact on drug usage and costs. The senator also requests drug companies voluntarily restrict DTC ads during the first two years a product is on the market.

DTC Advertising Bill Would Mandate Deeper Rx Discounts For Medicaid

Legislation introduced by Sens. Wyden (D-Ore.) and Sununu (R-N.H.) is aimed at reducing federal program costs for the most commonly advertised drugs. The Pharmaceutical Advertising & Prudent Purchasing Act also would require a study on ways to reduce Medicare costs for drugs promoted through DTC campaigns.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts